Cite
APA Citation
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S., & Moreau, P. (n.d.). carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet oncology, 18(10), 1327–1337. http://access.bl.uk/ark:/81055/vdc_100050154261.0x00001d